Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516199 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
Electronic (PDF)Add to Basket
EnterprisewideAdd to Basket
Live Chat Live Help Software for Website

Stakeholder Opinions: Gene Therapy - Gene Therapy to Deliver after 20 Years of Clinical Development

Datamonitor, Dec 2009, Pages: 90


  Description  
   Table of Contents   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

Gene therapy looks to be coming of age, with seven projects in Phase III clinical development and one project currently under regulatory review. A shift in development from pure gene replacement to using gene therapy as a therapeutic delivery tool has enhanced the technology's commercial potential over the last 10 years.

Scope

- In-depth analysis of the current gene therapy clinical pipeline.

- Analysis of key target indications for gene therapies and key companies active in the filed.

- Key opinion leader review of technologies driving clinical gene therapy.

- Identification of drivers and inhibitors to the commercial success of gene therapy.

Highlights of this title

Most of the indications being targeted in the current gene therapy pipeline are multifactorial rather than monogenic in etiology. Reflecting this trend, cancer has become the leading therapy area for gene therapy development, constituting nearly half of the clinical projects under development.

The development of highly engineered recombinant viruses has increased the safety of gene therapy. As clinical evidence for the enhanced safety of these vectors gathers over the next few years, the perceived risk/reward profile for gene therapy will change in some disease areas.

With endless lucrative targets for companies developing safe and efficient delivery of genes, the commercial potential of gene therapy remains high.

Key reasons to purchase this title

- Quantify the gene therapy pipeline.

- Assess the changing vectors and target indications for gene therapy.

- Identify the leading companies involved in gene therapy development.




Customers who bought this item also bought

Gene Therapy - Technologies, Markets and Companies

RNAi - Technologies, Markets and Companies

Gene Therapy - Global Strategic Business Report

Cell Therapy - Technologies, Markets and Companies

Antiviral Therapeutics - Technologies, Markets and Companies

Nanobiotechnology Applications, Markets and Companies

Gene Therapy-Industry Impact

Animal Biotechnology - Technologies, Markets and Companies

Biomarkers - Technologies, Markets and Companies

DNA Sequencing - Technologies, Markets and Companies



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds